Breakthrough in Antibiotic Resistance: Targeting Bacterial Enzymes
How the Study Uncovered a New Approach
Antibiotic resistance, a global health crisis linked to 4.7 million deaths in 2019, has seen a critical breakthrough. Researchers at Scripps Research discovered that disabling a bacterial enzyme called secreted antigen A (SagA) makes vancomycin-resistant Enterococcus faecium (VREfm) vulnerable to vancomycin. The study, published in *Nature Communications* on June 16, 2026, revealed that genetic deletion of SagA reduced the bacteria’s ability to divide, increasing susceptibility to the antibiotic.
According to Howard Hang, a professor at Scripps Research, “SagA remodels the cell wall so bacteria divide properly. Disrupting it makes the bacteria more sensitive to vancomycin.” The team also identified a chemical compound, pghi-4, which chemically blocks SagA, cutting the required vancomycin dose by up to 8-fold in lab tests.
Real-World Implications for Hospital Infections
VREfm, a hospital-acquired infection, is resistant to multiple antibiotics, including vancomycin. The study’s success in a mouse model of sepsis suggests the approach could translate to human treatments. “This is a promising new weapon in the arms race against antibiotic resistance,” Hang said.
The research highlights the potential of antibiotic adjuvants—compounds that enhance existing drugs. Unlike previous adjuvants, this strategy targets a family of enzymes (NlpC/P60 peptidoglycan hydrolases) never before successfully inhibited.
Future Potential and Challenges
The study’s findings open avenues for combating other resistant pathogens, such as tuberculosis and drug-resistant *Staphylococcus aureus*. Researchers are already developing second-generation compounds that combine pghi-4 with vancomycin.
However, challenges remain. VREfm strains often carry multiple SagA-like enzymes, which could reduce the treatment’s effectiveness. Scientists are investigating whether targeting these additional enzymes could broaden the approach.
Why This Matters for Global Health
Antibiotic Resistance: A Growing Threat
Antibiotic resistance is now classified as a “global health emergency” by the World Health Organization. In 2019, it contributed to 4.7 million deaths worldwide, with infections like VREfm becoming increasingly difficult to treat.
The Scripps study addresses a key gap: how to restore the efficacy of last-resort antibiotics. By targeting bacterial physiology rather than directly killing pathogens, the approach could delay the emergence of new resistances.
Comparing Past and Present Strategies
Traditional methods to combat resistance focus on developing new antibiotics, a process that takes years and costs billions. In contrast, adjuvants like pghi-4 offer a faster, more cost-effective solution. For example, while new antibiotics for VREfm have been scarce, this study demonstrates how existing drugs can be revitalized.
What’s Next for Antibiotic Research?
Expanding the Scope of Adjuvant Therapies
The success of pghi-4 has sparked interest in targeting other NlpC/P60 enzymes. Researchers are testing whether similar compounds could work against other resistant bacteria, including *E. coli* and *Pseudomonas aeruginosa*.
Hang emphasized the broader lesson: “Targeting basic bacterial processes can overcome resistance.” This aligns with recent studies showing that disrupting cell-wall synthesis or metabolic pathways can enhance antibiotic effectiveness.
Regulatory and Clinical Hurdles
Before clinical trials, the team must ensure the compounds are safe for human use. Animal studies showed reduced bacterial burden, but human trials are needed to confirm efficacy. Regulatory agencies like the FDA will likely require extensive testing before approval.
FAQ: Answers to Common Questions
What is vancomycin-resistant Enterococcus faecium (VREfm)?
VREfm is a type of bacteria that causes hospital-acquired infections and is resistant to multiple antibiotics, including vancomycin, a last-resort treatment.
Why is targeting SagA a breakthrough?
SagA is a key enzyme in bacterial cell-wall remodeling. Disabling it makes VREfm vulnerable to vancomycin, offering a way to revive an existing antibiotic without developing new ones.
Are there risks of side effects with this approach?
The study found no significant toxicity in mouse models, but human trials are needed to confirm safety. Researchers are also exploring whether the compound affects beneficial bacteria.
Did You Know?
Vancomycin, once considered a “last resort,” is now less effective against VREfm. The new approach could extend its usefulness for years.
Pro Tips for Staying Informed
Follow updates from the Scripps Research Institute and *Nature Communications* for developments in antibiotic adjuvants. Public health organizations like the WHO also track resistance trends globally.
Explore More
Learn how other innovations, like CRISPR-based therapies, are tackling antibiotic resistance. Visit our special report for deeper insights.
Call to Action
Stay ahead of the curve in medical advancements. Subscribe to our newsletter for regular updates on breakthroughs in global health. Share this article to spread awareness about the fight against antibiotic resistance.
